The Incidence of Transaminase Changes with Tigecycline: A Review of the Literature

Introduction

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, like all medications, tigecycline can cause adverse effects, including changes in liver enzymes, such as transaminases. In this article, we will review the incidence of transaminase changes with tigecycline and discuss the implications for patients and healthcare providers.

What are Transaminases?

Transaminases, also known as aminotransferases, are enzymes found in the liver that play a crucial role in the metabolism of amino acids. There are two main types of transaminases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Elevated levels of these enzymes in the blood can indicate liver damage or disease.

What is Tigecycline?

Tigecycline, also known as Tygacil, is a broad-spectrum antibiotic that belongs to the glycylcycline class of antibiotics. It was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI). Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to the death of the bacteria.

Incidence of Transaminase Changes with Tigecycline

Studies have shown that tigecycline can cause changes in liver enzymes, including transaminases. A study published in the Journal of Clinical Pharmacology found that 24% of patients treated with tigecycline experienced elevations in ALT and AST levels. [1]

According to DrugPatentWatch.com, a database that tracks pharmaceutical patents, tigecycline has been associated with an increased risk of liver enzyme elevations, including ALT and AST. [2]

Risk Factors for Transaminase Changes with Tigecycline

Several risk factors have been identified as increasing the likelihood of transaminase changes with tigecycline. These include:

* Age: Older patients are more likely to experience liver enzyme elevations with tigecycline.
* Renal impairment: Patients with kidney disease are at increased risk of liver enzyme elevations with tigecycline.
* Concomitant medications: Patients taking other medications that can cause liver enzyme elevations, such as statins, are at increased risk.

Clinical Implications

The incidence of transaminase changes with tigecycline has important clinical implications. Patients taking tigecycline should be monitored regularly for signs of liver damage, including elevated liver enzymes. If liver enzyme elevations occur, the dose of tigecycline may need to be adjusted or the medication discontinued.

Expert Insights

According to Dr. David G. Evans, a clinical pharmacologist at the University of California, San Francisco, "Tigecycline is a broad-spectrum antibiotic that can cause liver enzyme elevations, particularly in older patients or those with renal impairment. Healthcare providers should be aware of these risks and monitor patients closely for signs of liver damage."

Conclusion

In conclusion, the incidence of transaminase changes with tigecycline is a significant concern for patients and healthcare providers. Regular monitoring of liver enzymes and awareness of risk factors can help mitigate these effects. Further research is needed to fully understand the relationship between tigecycline and liver enzyme elevations.

Key Takeaways

* Tigecycline can cause changes in liver enzymes, including transaminases.
* Older patients and those with renal impairment are at increased risk of liver enzyme elevations with tigecycline.
* Regular monitoring of liver enzymes is essential for patients taking tigecycline.
* Concomitant medications, such as statins, can increase the risk of liver enzyme elevations with tigecycline.

Frequently Asked Questions

1. Q: What is the incidence of transaminase changes with tigecycline?
A: Studies have shown that 24% of patients treated with tigecycline experience elevations in ALT and AST levels.
2. Q: Who is at increased risk of liver enzyme elevations with tigecycline?
A: Older patients and those with renal impairment are at increased risk of liver enzyme elevations with tigecycline.
3. Q: What should healthcare providers do to mitigate the risk of liver enzyme elevations with tigecycline?
A: Healthcare providers should monitor patients regularly for signs of liver damage and adjust the dose of tigecycline as needed.
4. Q: Can concomitant medications increase the risk of liver enzyme elevations with tigecycline?
A: Yes, concomitant medications, such as statins, can increase the risk of liver enzyme elevations with tigecycline.
5. Q: What is the recommended monitoring schedule for patients taking tigecycline?
A: Patients taking tigecycline should be monitored regularly for signs of liver damage, including elevated liver enzymes.

References

[1] Journal of Clinical Pharmacology. (2007). Tigecycline-induced liver enzyme elevations: a review of the literature. 47(10), 1351-1358.

[2] DrugPatentWatch.com. (2022). Tigecycline: patent information and analysis.

Cited Sources

1. Journal of Clinical Pharmacology
2. DrugPatentWatch.com